ENDECE is focused on the development of NDC-1308, a novel therapeutic agent designed to address neurodegenerative diseases, particularly Multiple Sclerosis (MS). NDC-1308 operates through a unique dual mechanism of action that not only induces remyelination of demyelinated axons in the central nervous system (CNS) but also inhibits further demyelination. This innovative approach sets NDC-1308 apart from existing MS treatments. Additionally, the compound promotes an anti-inflammatory response by upregulating the expression of lipoprotein lipase (LPL) in macrophages, facilitating their polarization to a pro-repair state, which is crucial for restoring function and improving the quality of life for patients.

Beyond MS, ENDECE's research pipeline includes therapies targeting various conditions such as Alzheimer’s Disease, Niemann-Pick disease type C, and Acute Respiratory Distress Syndrome (ARDS). The company employs a proprietary library of compounds aimed at activating specific biological pathways to halt disease progression and repair damage. Notably, NDC-1308 is administered intranasally, allowing for direct delivery to the CNS, which enhances its therapeutic potential. This innovative delivery method, combined with the drug's ability to modulate inflammatory responses and promote repair mechanisms, positions ENDECE as a leader in the development of treatments for chronic and debilitating diseases with limited existing options.

United States

Acute Respiratory Distress Syndrome (ARDS) is a life-threatening condition resulting in a reduction of oxygen that reaches the blood stream and vital organs. Few effective therapeutic modalities exist to treat ARDS, leading to a high mortality rate. 

ENDECE designed NDC-1308 to reduce the ability of SARS-CoV-2 / COVID-19 to replicate within the pulmonary system, and reduce inflammation.

Genetic Diseases

Lung Diseases

Lymphatic Diseases

Metabolic Diseases

Nervous System Diseases

ENDECE

Alzheimer's disease

Multiple sclerosis

Neuromyelitis optica spectrum disorder

Niemann Pick Disease Type C

Osmotic demyelination syndrome

NDC-1308

Small Molecule Pharmaceuticals

Acute respiratory distress syndrome

Lung Inflammation

Wisconsin

Therapeutic

ENDECE

Company Details